Literature DB >> 26984943

CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment.

Yonghao Cao1, Alyssa Nylander2, Sriram Ramanan2, Brittany A Goods2, Gerald Ponath2, Rana Zabad2, Veronica L S Chiang2, Alexander O Vortmeyer2, David A Hafler2, David Pitt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26984943      PMCID： PMC5573201          DOI： 10.1212/WNL.0000000000002594

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis.

Authors:  A A Hurwitz; T J Sullivan; M F Krummel; R A Sobel; J P Allison
Journal:  J Neuroimmunol       Date:  1997-03       Impact factor: 3.478

2.  Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis.

Authors:  Yonghao Cao; Brittany A Goods; Khadir Raddassi; Gerald T Nepom; William W Kwok; J Christopher Love; David A Hafler
Journal:  Sci Transl Med       Date:  2015-05-13       Impact factor: 17.956

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma.

Authors:  Edward J Gettings; Christopher T Hackett; Thomas F Scott
Journal:  Mult Scler       Date:  2014-09-25       Impact factor: 6.312

5.  Radiologic and histologic consequences of radiosurgery for brain tumors.

Authors:  Ahmed Alomari; Philipp J Rauch; Maria Orsaria; Frank J Minja; Veronica L Chiang; Alexander O Vortmeyer
Journal:  J Neurooncol       Date:  2014-01-18       Impact factor: 4.130

6.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

Authors:  Bing Liao; Sheetal Shroff; Carlos Kamiya-Matsuoka; Sudhakar Tummala
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245
  7 in total
  30 in total

1.  Neurotoxicities associated with immune checkpoint inhibitor therapy.

Authors:  Sophie L Duong; Frank J Barbiero; Richard J Nowak; Joachim M Baehring
Journal:  J Neurooncol       Date:  2021-01-17       Impact factor: 4.130

Review 2.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

Review 3.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

4.  Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.

Authors:  Qi Wu; Elizabeth A Mills; Qin Wang; Catherine A Dowling; Caitlyn Fisher; Britany Kirch; Steven K Lundy; David A Fox; Yang Mao-Draayer
Journal:  JCI Insight       Date:  2020-02-13

Review 5.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

6.  Report on the 2018 Cancer, Autoimmunity, and Immunology Conference.

Authors:  Colleen S Curran; Connie L Sommers; Howard A Young; Katarzyna Bourcier; Marie Mancini; Elad Sharon
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

Review 7.  Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.

Authors:  Liliana E Lucca; David A Hafler
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

8.  Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder.

Authors:  Matthew K Schindler; Stefania Pittaluga; Yoshimi Enose-Akahata; Helen C Su; V Koneti Rao; Amy Rump; Steven Jacobson; Irene Cortese; Daniel S Reich; Gulbu Uzel
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

9.  Neurological complications of new chemotherapy agents.

Authors:  Alicia M Zukas; David Schiff
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

Review 10.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Authors:  Lidia M Yshii; Reinhard Hohlfeld; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2017-11-06       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.